Teva Pharmaceutical Industries (TEVA) Cash from Operations (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Cash from Operations across 10 years of filings, most recently posting 40000000.0 for Q1 2026.

• Quarterly Cash from Operations rose 61.9% year-over-year to 40000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1714000000.0 (up 35.39% YoY) and the FY2025 annual result came in at 1649000000.0, up 32.24% from the prior year.
• Cash from Operations retreated to 40000000.0 in Q1 2026, from 1158000000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 1184000000.0 in Q4 2023 and troughed at 145000000.0 in Q1 2023.
• A 5-year average of 342000000.0 and a median of 227000000.0 in 2025 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2023 — Cash from Operations tumbled 195.92% — and 2024, when it soared 13760.0%.
• Tracing TEVA's Cash from Operations over 5 years: stood at 973000000.0 in 2022, then climbed by 21.69% to 1184000000.0 in 2023, then plunged by 51.44% to 575000000.0 in 2024, then surged by 101.39% to 1158000000.0 in 2025, then slumped by 103.45% to 40000000.0 in 2026.
• Business Quant data shows TEVA's Cash from Operations at 40000000.0 in Q1 2026, 1158000000.0 in Q4 2025, and 369000000.0 in Q3 2025.